[1]石洲宝,刘敏科,黄生辉,等.安神二号胶囊联合盐酸文拉法辛缓释片对焦虑障碍患者认知、社会功能的影响[J].西部中医药,2013,26(04):4-7.
　SHI Zhoubao,LIU Minke,HUANG Shenghui,et al.Effects of A nShen Capsule No.2 and Venlafaxine Hydrochloride Sustained-release Tablets on Cognition and Social Function of Patients with Anxiety Disorder[J].Western Journal of Traditional Chinese Medicine,2013,26(04):4-7.
点击复制

安神二号胶囊联合盐酸文拉法辛缓释片对焦虑障碍患者认知、社会功能的影响
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
26
期数:
2013年04期
页码:
4-7
栏目:
出版日期:
2013-04-15

文章信息/Info

Title:
Effects of A nShen Capsule No.2 and Venlafaxine Hydrochloride Sustained-release Tablets on Cognition and Social Function of Patients with Anxiety Disorder
文章编号:
1004-6852(2013)04-0004-04
作者:
石洲宝，刘敏科，黄生辉，唐珂，高丽波
甘肃中医学院附属医院脑病科，甘肃 兰州 730020
Author(s):
SHI Zhoubao, LIU Minke, HUANG Shenghui, TANG Ke, GAO Libo
Department of Encephalopathy in University Hospital of Gansu Traditional Chinese Medicine, Lanzhou 730020, China
关键词:
焦虑障碍; 认知及社会功能; 安神二号胶囊; 盐酸文拉法辛缓释片
Keywords:
anxiety disorder;  cognition and social function;  AnShen capsule No.2;  venlafaxine hydrochloride sustained-release tablets
分类号:
R749.7+2
文献标志码:
A
摘要:
目的：探讨安神二号胶囊与盐酸文拉法辛对焦虑障碍认知及社会功能的影响。方法：将 180 例符合 DSM-Ⅳ标准的焦虑障碍患者随机分为治疗组和对照组各 90 例，观察时间均为 8 周。以 HAMA、HAMD、WCST及社会功能 SDSS 作为疗效评价工具。结果：治疗第 8 周末，2 组 HAMA、HAMD 及社会功能 SDSS 评分均较基线降低，WCST 指标中，除了治疗组持续应答数外均获改善，差异均有统计学意义(P＜0.01)；治疗组 HAMA、HAMD 评分的降低较对照组更为明显。与基线比较，治疗组 WCST 分类数较基线治疗组增加（-1.0±1.5），对照组增加（-0.4±1.1）;正确应答数治疗组增加（-10.1±15.4），对照组增加（-5.0±16.3）；错误应答数治疗组降低（15.1±25.5）,对照组降低（7.0±23.3）；概念化水平百分数治疗组增加（-14.9±22.8），对照组增加（-9.2±26.3）。SDSS 评分较基线治疗组降低(6.1±4.3)分，对照组降低(4.5±3.6)分。组间上述各项比较，差异均有统计学意义(P＜0.05)。结论：安神二号胶囊配合盐酸文拉法辛治疗，对焦虑障碍患者的焦虑障碍、认知及社会功能的改善更为有效。
Abstract:
Objective: To evaluate the effects of AnShen capsule No.2 combined with venlafaxine hydrochloride sustained-release tablets on cognition and social function of patients with anxiety disorder. Method: All 180 patients,who met the standard of DSM- Ⅳ , were randomly divided into the treatment group and the control group, the observation time was eight weeks. Hamilton anxiety (HAMA), Hamilton depression scale (HAMD), Wisconsin card sorting test (WCST) and social disability screening schedule (SDSS) were taken as the tools to assess clinical effects.Result: By the end of 8th week, HAMA, HAMD and SDSS of both groups were lower than the baseline and the difference showed statistical meanings in improvements of WCST indexes except the numbers of persistent responses in the treatment group (P＜0.01); the decrease of the treatment group was more significant than that of the control group in the score of HAMA and HAMD. Compared with the baseline, WSCT of the treatment group increased (-1.0±1.5), and the control group increased (-0.4±1.1); correct responses of the treatment group increased(-10.1±15.4), and the control group raised (-5.0依16.3); wrong responses of the treatment group declined (15.1依25.5)and the control group lowered (7.0± 23.3); the conceptual level of the treatment group increased (-14.9±22.8), the control group raised (-9.2±26.3). The scale of SDSS in the treatment group decreased (6.1±4.3) and the control grouplowered (4.5±3.6). Comparisons between both groups had differences and they showed statistical meaning (P＜0.05).Conclusion: AnShen capsule No.2 combined with Venlafaxine hydrochloride sustained-release tablets are effective in improving anxiety disorder, cognition and social function in patients.

备注/Memo

备注/Memo:
收稿日期：2012-08-27 作者简介：石洲宝(1965—)，男，硕士研究生导师，副主任医师。研究方向：精神(心理)障碍的临床研究。
更新日期/Last Update: 2013-04-15